Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice.
J Virol
; 72(1): 807-10, 1998 Jan.
Article
em En
| MEDLINE
| ID: mdl-9420291
ABSTRACT
Immunotherapy with antibodies against respiratory syncytial virus (RSV) is a treatment option given the absence of any vaccine or other available satisfactory treatment. We selected one of our monoclonal antibodies, RS-348, that is highly neutralizing. We showed that a single peptide (PEP3H) derived from complementarity-determining region 3 (CDR3) of its heavy chain was capable of neutralizing the virus in vitro. When intranasally administered 24 h before challenge, this peptide protected BALB/c mice against RSV lung infection. These results indicate that a single CDR can be effective against RSV infection.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vírus Sinciciais Respiratórios
/
Região Variável de Imunoglobulina
/
Infecções por Vírus Respiratório Sincicial
/
Anticorpos Monoclonais
/
Anticorpos Antivirais
Limite:
Animals
Idioma:
En
Revista:
J Virol
Ano de publicação:
1998
Tipo de documento:
Article
País de afiliação:
França